OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
|Articles|February 1, 2005
- Volume 0 0
Reminyl Will Receive New Name
Advertisement
Johnson & Johnson is renaming itsAlzheimer's disease drug Reminyl(galantamine HBr). Although the companyand the FDA have not agreed onthe new name, the change is expectedto be introduced by the end of March2005. The decision to changeReminyl's name comes after 2 patientsdied when they were mistakenly givena similar-sounding drug—Amaryl(glimepiride). Amaryl (Sanofi-Aventis)is indicated for the treatment of diabetes.The deaths were caused by hypoglycemiaor low blood sugar when thepatients were given Amaryl.
Articles in this issue
almost 22 years ago
Issues in the Treatment of Patients with Hypothyroidismalmost 22 years ago
Health Organizations Favor Electronic Health Recordsalmost 22 years ago
Therapeutic Management of Bronchitisalmost 22 years ago
Program Advocates for Timely Prescription Refillsalmost 22 years ago
Cardinal Backs RFID Technologyalmost 22 years ago
Agreement Improves Point of Carealmost 22 years ago
Decision Unpopular with Health Care Professionalsalmost 22 years ago
Unemployment Benefits Denied When Pharmacist Quits Work Because of Stressalmost 22 years ago
The Importance of the Order of Drug Administrationalmost 22 years ago
Beware of Erroneous Daily Oral Methotrexate Dosing!Advertisement
Related to this article
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
The Most Accessible Healthcare Professional—But Accessible to Whom?
4
Garlic: Untangling the Complexities of a “Natural” Remedy
5